Abstract
BACKGROUND: Medulloblastoma is the most common malignant brain tumor in children, classified into four primary molecular subgroups: WNT, SHH, Group 3, and Group 4, each exhibiting significant molecular heterogeneity and varied survival outcomes. Accurate classification of these subgroups is crucial for optimizing treatments and improving patient outcomes. DNA methylation profiling is a promising approach for subgroup classification; however, its application is still evolving, with ongoing efforts to improve accessibility and develop more accurate classification methods. OBJECTIVES: This study aims to develop a supervised machine learning-based framework using Illumina 450K methylation data to classify medulloblastoma into seven molecular subgroups: WNT, SHH-Infant, SHH-Child, Group3-LowRisk, Group3-HighRisk, Group4-LowRisk, and Group4-HighRisk, incorporating age and risk factors for enhanced subgroup differentiation. METHODS: The proposed model leverages six metagenes, capturing the underlying patterns of the top 10,000 probes with the highest variances from Illumina 450K data, thus enhancing methylation data representation while reducing computational demands. RESULTS: Among the models evaluated, the SVM achieved the highest performance, with a mean balanced accuracy 98% and a macro-averaged AUC of 0.99 in an independent validation. This suggests that the model effectively captures the relevant methylation patterns for medulloblastoma subgroup classification. CONCLUSIONS: The developed SVM-based model provides a robust framework for accurate classification of medulloblastoma subgroups using DNA methylation data. Integrating this model into clinical decision making could enhance subgroup-directed therapies and improve patient outcomes.